Previous close | 8.65 |
Open | 8.75 |
Bid | 8.80 x N/A |
Ask | 9.60 x N/A |
Day's range | 8.75 - 8.75 |
52-week range | 5.93 - 12.30 |
Volume | |
Avg. volume | 62 |
Market cap | 7.384B |
Beta (5Y monthly) | 1.31 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.36 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 studyIMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort dataPotential best-in-class profile enables broad and exciting portfolio of indic
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this studyPriovant expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU)
Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitisIMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg multiple-ascending dose studiesIMVT-1402 showed no statistically significant dose-rel